Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ: OKYO )

1.110 -0.050 (-4.31%)
Streaming Delayed Price Updated: 2:45 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
OKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public... 
Via Benzinga
Why Is Okyo Pharma (OKYO) Stock Up 13% Today?
Okyo Pharma (OKYO) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of DED treatment OK-101. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
From OKYO Pharma LTD
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a... 
Via Benzinga
UBER, LYFT Stocks Rise as California Court Rules Drivers Are Contractors
Uber (UBER) and Lyft (LYFT) stock are on the rise Tuesday after a court ruled that the companies' drivers are contractors. 
Via InvestorPlace
Why Is OKYO Pharma (OKYO) Stock Down 10% Today?
OKYO Pharma (OKYO) stock is heading lower on Tuesday after the company revealed details of a stock offering for its ADSs. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with an overview of the biggest pre-market stock movers investors need to keep an eye on for Tuesday! 
Via InvestorPlace
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
From OKYO Pharma LTD
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
From OKYO Pharma LTD
Via GlobeNewswire
SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
US Stocks Edge Lower; Dollar Tree Profit Beats Views
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 30 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.09% to 32,626.82 while... 
Via Benzinga
Why Is Helbiz (HLBZ) Stock Up 37% Today?
Helbiz (HLBZ) stock is on the move Wednesday despite a lack of hard news concerning the electric bike and scooter company. 
Via InvestorPlace
XPEV Stock Alert: What to Know as Xpeng Reports February Vehicle Deliveries
Xpeng (XPEV) stock is worth checking on Wednesday after the electric vehicle (EV) company released delivery data for February. 
Via InvestorPlace
Why Is Novavax (NVAX) Stock Down 26% Today?
Novavax (NVAX) stock is dropping on Wednesday after the vaccine company warned investors about the state of its business. 
Via InvestorPlace
Why Is OKYO Pharma (OKYO) Stock Down 31% Today?
OKYO Pharma (OKYO) stock is taking a beating on Wednesday despite recent progress toward a Phase 2 clinical trial for dry eye treatment. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
OKYO Pharma's Drug OK-101 Clears Customs in the US; To Be Used In Phase 2, First-In-Human, Clinical Trial For Patients With Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) recently announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which was... 
Via Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
By David Willey, Benzinga 
Via TheNewswire.com
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution 
Via News Direct
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.